Heart & blood pressure · Omaha area, NE
Heart and blood pressure studies in Omaha area, NE
28 recruiting studies have a site in the Omaha area. This page includes nearby cities such as Bellevue, Papillion, Elkhorn, Lincoln.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in…
Bristol-Myers Squibb
- Location
- Lincoln, NE
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
University of Nebraska
- Location
- Omaha, NE
- Eligibility basics
- Ages 50–75
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Lincoln, NE + 64 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Pfizer
- Location
- Lincoln, NE + 27 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Omaha, NE + 58 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
CVRx, Inc.
- Location
- Omaha, NE + 16 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
NORM-HF Pivotal Study
Foundry Innovation & Research 1, Limited (FIRE1)
- Location
- Omaha, NE + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- Lincoln, NE + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- Omaha, NE + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- Omaha, NE + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Lincoln, NE + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Omaha, NE + 80 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Insmed Incorporated
- Location
- Omaha, NE + 10 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Omaha, NE + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Lincoln, NE + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Omaha, NE + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Genentech, Inc.
- Location
- Omaha, NE + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
- Location
- Omaha, NE + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Lincoln, NE + 117 other US sites
- Eligibility basics
- Ages 18–99
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Omaha, NE + 46 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Omaha, NE + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Omaha, NE + 112 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
- Location
- Omaha, NE + 56 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
XVIVO Perfusion
- Location
- Omaha, NE + 13 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.